[1] | Scheen, J.A., 1997, Drug treatment of non-insulin dependent diabetes mellitus in the 1990s. Achievements and future development., Drugs, 54, 355-368. |
[2] | Vinik, A.I., and Vinik, E., 2003, Prevention of the complications of diabetes., Am. J. Manage Care, 9, S63-S80. |
[3] | Aronson, D., 2008, Hyperglycemia and pathobiology of diabetic complications., Adv. Cardiol., 45, 1-16. |
[4] | Borchers, A.T., Uibo, R., Gershwin, M.E., 2010, The geoepidemiology of type 1 diabetes., Autoimmun Rev, 9(5), A355-A365. |
[5] | Zandonella, C., 2003, Cell nanotechnology: The tiny toolkit., Nature, 423, 10-12. |
[6] | Brown, S. D., ativo, P., Smith, J.A., Stirling, D., and et al., 2010, Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin., Am. Chem. Soc., 132(13), 4678-4684. |
[7] | Dykman, L. A., and Khlebtsov, N.G., 2011, Gold Nanoparticles in Biology and Medicine: Recent Advances and Prospects., ACTA NATURAE, 3 (2), 34-55. |
[8] | Venkatachalam, M., Govindaraju, K., Mohamed, S. A., et al., 2013, Functionalization of gold nanoparticles as antidiabetic nanomaterial, Spectrochim., Acta A Mol. Biomol. Spectrosc., 116, 331–338. |
[9] | Rajeswari, A., Kumar, V.G., Karthick, V., et al., 2013, Hydrothermal synthesis of hydroxyapatite plates prepared using low molecular weight heparin (LMWH), Colloid Surf., B. Biointerf., 111, 764–768. |
[10] | Kumar, V.G., Gokavarapu, S.D., Rajeswari, A., et al., 2011, Facile green synthesis of gold nanoparticles using leaf extract of antidiabetic potent Cassia auriculata, Colloid Surf., B. Biointerf., 87, 159–163. |
[11] | Shanmugasundaram, K.R., Panneerselvam, C., Samudram, P., and Shanmugasundaram, B.E.R., 1981, The nsulinotropic activity of Gymnema sylvestre, R.Br. an indian medical herb used in controlling Diabetes mellitus., Pharmacol. Res. Commun., 13(5), 475–486. |
[12] | Kanetkar, P., Singhal, R., Kamat, M., and Gymnema sylvestre, 2007, a memoir., J. Clin. Biochem. Nutr., 41, 77–81. |
[13] | Lechleitner, M., Koch, T., Herold, M., Dzien, A. and Hoppichler, F., 2000, Tumour necrosis factor- alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors., Journal of Internal Medicine, 248, 67-76. |
[14] | Zorena, K., Myśliwska, J., Myśliwiec, M., et al., 2007, Relationship between serum levels of tumor necrosis factor-alpha and interleukin-6 in diabetes mellitus type 1 children., Central European Journal of Immunology, 32(3), 124-128. |
[15] | Jeon, KI, Byun, MS, Jue, 2003, DM: Gold compound auranofin inhibits Ikappa B kinase (IKK) by modifying Cys-179 of IKKbeta subunit., Exp Mol Med., 35(2), 61-66. |
[16] | Kim, N.H., Lee, M.Y., Park, S.J., Choi, J.S., et al., 2007, Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3, Immunology, 122, 607-614. |
[17] | Norton, S., 2008, A brief history of potable gold., Mol Interv., 8(3), 120-125. |
[18] | Martínez-Gutierrez, F., Thi, E.P., Silverman, J.M., de Oliveira, C.C., et al., 2012, Antibacterial activity, inflammatory response, coagulation and cytotoxicity effects of silver nanoparticles., Nanomedicine, 8, 328-336. |
[19] | Khan, H.A., Abdelhalim, M.A.K., Alhomida, A.S. and Al Ayed, M.S., 2013, Transient increase in IL-1β, IL-6 and TNF-α gene expression in rat liver exposed to gold nanoparticles., Genet. Mol. Res., 12 (4), 5851-5857. |
[20] | Zhang, Q., Hitchins, V.M., Schrand, A.M., Hussain S.M., et al., 2011, Uptake of gold nanoparticles in murine macrophage cells without cytotoxicity or production of pro-inflammatory mediators., Nanotoxicology, 5, 284-295. |
[21] | Yen, H.J., Hsu, S.H. and Tsai, C.L. 2009, Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes., Small, 5, 1553-1561. |
[22] | Amessou, M, Bortoli, S, Liemans, V, Collinet, et al., 1999, Treatment of streptozotocin-induced diabetic rats with vanadate and phlorizin prevents the over-expression of the liver insulin receptor gene., Eur J Endocrinol., 140(1), 79-86. |
[23] | Lutz, A.J. and Pardridge, W.M., 1993, Insulin therapy normalizes glucose transporter mRNA but not immunoreactive transporter protein in streptozotocin-diabetic rats., Metab., 42, 939-944. |
[24] | Toba, H., Sawai, N., Morishita, M., Murata, S., et al., 2009, chronic treatmeant with recombinant erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin induced diabetic rat., Eur. J. Pharmacol. , 612, 106-114. |
[25] | Yves, M.H. and Theo, F.M., 2007, The effect of low dose insulin on mechanical sensitivity and allodynia in type1 diabetes neuropathy. Neurosc., Letters. , 417, 149-154. |
[26] | Palsamy, P. and Subramanian, S. 2008, Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin nicotinamide induced experimental diabetic rats., Biomedicine & Pharmacotherapy, 62(9), 1-8. |
[27] | Selvaraj, B., Kalimuthu, K., Muthuirulappan, S., SureshBabu, R., et al., 2010, Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice., J Nanobiotechnology, 8,16. |
[28] | Selim, M.E., Hendi, A.A. and Alfallaj, E., 2016, The possible counteractive effect of gold nanoparticles against streptozotocin-induced type 1 diabetes in young male albino rats., Pak. J. Pharm. Sci., 29(3), 823-836. |
[29] | Trinder, P., 1969, Enzymatic determination of glucose., An. Clin. Bioch, 6, 24-27. |
[30] | Starr, J.I., Mako, M.E., Juhn, D., and Rubenstein, A.H., 1978, Measurement of serum pro-insulin–like material: cross reactivity of porcine and human proinsulin., J. Lab. Clin. Med., 91, 691-692. |
[31] | Murray, R., Kaplan, A., Rubaltelli, F. F. and Hammerman, C., 1984, The C.V. Mosby Co. St Louis., Toronto. Princeton, Clin. Chem., 1112-119. |
[32] | Young, D.S., 1995, Effects of drugs on Clinical Lab., Tests, 4th ed AACC Press. |
[33] | Tietz, N.W., Pruden, E.L. and Siggard-Andersen, O., Clinical Guide to Laboratory Tests, 3rd edition, W. B. Saunders. Company: Philadelphia., 1995. |
[34] | Wenger, C., Kaplan, A., Rubaltelli, F.F. and Hammerman, C., 1984, Alkaline phosphatase., Clin. Chem. The C.V. Mosby Co. St Louis. Toronto. Princeton., 1094-1098. |
[35] | Mukherjee, P., Bhattacharya, R., Wang, P., Wang, L., et al., 2005, Antiangiogenic properties of gold nanoparticles., Clin Cancer Res, 11, 3530-3534. |
[36] | BarathManiKanth, S., Kalishwaralal, K., Sriram, M., Pandian, S.R.K., et al., 2010, Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice., Journal of Nanobiotechnology, 8,16. |
[37] | Karthick, V., Kumar, V.G., Dhas, T.S, Singaravelu, G., et al., 2014, Effect of biologically synthesized gold nanoparticles on. Alloxan-induced diabetic rats— An in vivo approach., Colloids and Surfaces B: Biointerfaces, 122, 505–511. |
[38] | Doudi, M. and Setorki, M., 2013, The effect of gold nanoparticle on renal function in rats., Nanomed J, 1 (3), 171-179. |
[39] | Mak, A. and Moussa, A.S.A., 2013, The gold nanoparticle size and exposure duration effect on the liver and kidney function of rats: In vivo., Saudi J Biol Sci., 20(2), 177-181. |
[40] | Christen, U.1., Wolfe, T., Möhrle, U., Hughes, A.C., et al., 2001, A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis., J Immunol., 166(12), 7023-32. |